Spero Therapeutics, Inc. (SPRO)
| Market Cap | 69.88M -37.3% |
| Revenue (ttm) | 47.00M -3.3% |
| Net Income | 7.38M |
| EPS | 0.13 |
| Shares Out | 58.23M |
| PE Ratio | 9.39 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,779 |
| Open | 1.210 |
| Previous Close | 1.210 |
| Day's Range | 1.181 - 1.220 |
| 52-Week Range | 1.080 - 3.080 |
| Beta | 1.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, man... [Read more]
Financial Performance
Financial StatementsNews
Spero Therapeutics files $300M mixed securities shelf
17:05 EDT Spero Therapeutics (SPRO) files $300M mixed securities shelf
Spero Therapeutics Registration statement: Registration filing
Spero Therapeutics filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Spero Therapeutics Earnings Call Transcript: Q2 2026
FDA approved Utebzi, enabling a strategic pivot to immunology with the in-licensing of SP001 and $105M non-dilutive financing. Cash runway now extends into H2 2029, with a phase II trial for SP001 in IgG4-RD planned for 2027.
Spero Therapeutics Quarterly report: Q2 2026
Spero Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Spero Therapeutics Earnings release: Q2 2026
Spero Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and...
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and...
Spero Therapeutics appoints Debra Jeske Zack as chief medical officer
Spero Therapeutics (SPRO) announced the appointment of Debra Jeske Zack as chief medical officer. Zack will lead Spero’s clinical development strategy and organization as the company advances its immu...
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero's clinical leadership team as the Company advances SP001, a Phase...
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' experimental autoimmune disease treatment in a deal worth up to about $1.1 billion, the ...
Spero Therapeutics secures $105M non-dilutive financing to develop SP001
Spero Therapeutics (SPRO) announced a $105M non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR. Under the agreement, HCRx will receive a p...
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
Spero Therapeutics (SPRO) and Innovent Biologics (IVBXF) announced an exclusive license agreement for SP001, a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to de...
Spero Therapeutics, Innovent Biologics announce exclusive IBI355 license pact
Innovent Biologics and Spero Therapeutics (SPRO) announced an exclusive license agreement for IBI355, a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, ...
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology an...
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001) Innovent will...
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) today announced an exclusive lic...
Spero Therapeutics Slides: Company presentation
Spero Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 13, 2026.
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activate...
Spero Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, an increase in authorized shares, and a new stock incentive plan. All proposals passed with a quorum present, and voting results will be published in a Form 8-K.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
GSK, Spero Therapeutics announce FDA approval of Utebzi
GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections including ...
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its...
Spero Therapeutics Earnings release: Q1 2026
Spero Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Spero Therapeutics Quarterly report: Q1 2026
Spero Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.